- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
0.001
0.000(0.00%)
Delayed Data·
Fair Value
An estimate of a Syros Pharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.001
0.008
52 wk Range
0.001
3.400
SYRS Financial Summary
A brief financial summary of Syros Pharmaceuticals Inc as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.
Key Ratios
Statements Highlights
| Period Ending: | 2014 31/12 | 2015 31/12 | 2016 31/12 | 2017 31/12 | 2018 31/12 | 2019 31/12 | 2020 31/12 | 2021 31/12 | 2022 31/12 | 2023 31/12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenues | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 1.98 | 15.09 | 23.49 | 14.88 | 9.94 | |
Gross Profit | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 1.98 | 15.09 | 23.49 | -97.06 | -98.22 | |
Operating Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -77.74 | -82.3 | -99.42 | -126.36 | -126.5 | |
Net Income | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -75.44 | -84.04 | -86.56 | -94.65 | -164.57 | |
Total Assets | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 149.98 | 213.25 | 182.94 | 244.49 | 168.17 | |
Total Current Liabilities | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 23.52 | 28.62 | 31.51 | 30.78 | 36.68 | |
Total Equity | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 79.18 | 90.55 | 85.22 | 127.74 | 16.66 | |
Levered Free Cash Flow | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -67.03 | -18.45 | -50.79 | -66.58 | -66.66 | |
Cash from Operations | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -60.25 | -57.36 | -99.54 | -123.07 | -109.71 | |
Cash from Investing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -11.73 | 46.66 | -52.65 | 67.19 | 37.34 | |
Cash from Financing | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | 65.99 | 142.95 | 70.51 | 131.05 | 43.46 | |
Net Change in Cash | aa.aa | aa.aa | aa.aa | aa.aa | aa.aa | -6 | 132.25 | -81.68 | 75.17 | -28.91 | |
* In Millions of USD (except for per share items)
Analyst Ratings
0 Buy
1 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 0.000
FAQ
What was Syros Pharma's net income for the latest quarter?
Syros Pharma's net income for the latest quarter was -6.40.
What is Syros Pharma's net profit margin on a TTM basis?
Syros Pharma's trailing twelve months (TTM) net profit margin is -1,656.34%.
How does Syros Pharma's debt to equity ratio compare to industry standards?
Syros Pharma's total debt-to-equity ratio is -541.45%.
What is Syros Pharma's return on investment on a TTM basis?
Syros Pharma's trailing twelve months (TTM) return on investment (ROI) is -776.96%.
Did Syros Pharma gain or lose cash last quarter?
In the latest quarter, Syros Pharma's net change in cash was -20.69 million.
What were Syros Pharma's total assets and liabilities in the latest quarter?
As of the latest quarter, Syros Pharma reported total assets of 85.00 million and total liabilities of 28.39 million.
What is Syros Pharma's gross margin on a TTM basis?
Syros Pharma's trailing twelve months (TTM) gross margin is -22,862.95%.
What was Syros Pharma's revenue per share for the latest quarter?
Syros Pharma's revenue per share for the latest quarter was 3.09.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.